The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 25 of the 34 sources its claims cite were checked for support.
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
Open accessAbstract
BACKGROUND: Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable. METHODS: The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene sequencing. In an observational study, we examined associations between microbiota diversity and mortality using Cox proportional-hazards analysis. For stratification of the cohorts into higher- and lower-diversity groups, the median diversity value that was observed at the study center in New York was used. In the analysis of independent cohorts, the New York center was cohort 1, and three centers in Germany, Japan, and North Carolina composed cohort 2. Cohort 1 and subgroups within it were analyzed for additional outcomes, including transplantation-related death. RESULTS: We profiled 8767 fecal samples obtained from 1362 patients undergoing allogeneic hematopoietic-cell transplantation at the four centers. We observed patterns of microbiota disruption characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota was associated with a lower risk of death in independent cohorts (cohort 1: 104 deaths among 354 patients in the higher-diversity group vs. 136 deaths among 350 patients in the lower-diversity group; adjusted hazard ratio, 0.71; 95% confidence interval [CI], 0.55 to 0.92; cohort 2: 18 deaths among 87 patients in the higher-diversity group vs. 35 deaths among 92 patients in the lower-diversity group; adjusted hazard ratio, 0.49; 95% CI, 0.27 to 0.90). Subgroup analyses identified an association between lower intestinal diversity and higher risks of transplantation-related death and death attributable to graft-versus-host disease. Baseline samples obtained before transplantation already showed evidence of microbiome disruption, and lower diversity before transplantation was associated with poor survival. CONCLUSIONS: Patterns of microbiota disruption during allogeneic hematopoietic-cell transplantation were similar across transplantation centers and geographic locations; patterns were characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota at the time of neutrophil engraftment was associated with lower mortality. (Funded by the National Cancer Institute and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 4 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Each of these outcomes, as well as overall survival, has been associated in single-center studies with features of the intestinal microbiota in the period after hematopoietic-cell transplantation.2–4,8–15”
§ Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation > Abstract > CONCLUSIONS
What the sources say
- Supportedcites [2] Holler E, Butzhammer P, Schmid K, Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 640– 5. 24492144 PMC4973578 source
The Results (16S rRNA Gene Sequencing) link post-transplant intestinal microbiota features—particularly enterococcal abundance—with gastrointestinal GVHD. In this multiply cited sentence, the paper supports the GVHD component; it need not establish the other outcomes covered by the other citations. (LLM, conf=0.91)
- Supportedcites [3] Taur Y, Xavier JB, Lipuma L, Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905– 14. 22718773 PMC3657523 source
The Discussion reports that post-transplant intestinal microbiota changes correlated with subsequent bloodstream infection, and identifies this as a study at one medical center. This source supports the infection component of the multi-citation sentence; it need not establish every outcome listed there. (LLM, conf=0.91)
- Supportedcites [4] Golob JL, Pergam SA, Srinivasan S, Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin Infect Dis 2017; 65: 1984– 91. 29020185 PMC5850019 source
The Abstract reports an association between stool microbiota features measured after HCT, at neutrophil recovery, and subsequent severe acute GVHD. The Discussion identifies this as a single-center study. This citation supports the GVHD part of the multi-citation sentence; it need not establish every outcome listed. (LLM, conf=0.93)
- Partly supportedcites [8] Taur Y, Jenq RR, Perales MA, The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124: 1174– 82. 24939656 PMC4133489 sourceExperimental — accuracy not yet measured
The Results report that intestinal microbial diversity at engraftment was associated with overall survival and transplant-related mortality; deaths due to GVHD or infection were more frequent in patients with low diversity. The Discussion says there was no discernible association with mortality from relapse or disease progression. The paper does not establish an association between post-HCT microbiota features and organ toxicity. (LLM, conf=0.90)
- Partly supportedcites [9] Jenq RR, Taur Y, Devlin SM, Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 1373– 83. 25977230 PMC4516127 sourceExperimental — accuracy not yet measured
The Results section reports that post-transplant Blautia abundance was associated with improved overall survival, reduced GVHD-related mortality, and reduced relapse-related mortality. It does not establish an association with relapse itself, infection, or organ toxicity, so this source supports only part of the multi-outcome claim. (LLM, conf=0.88)
- Partly supportedcites [10] Shono Y, Docampo MD, Peled JU, Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 2016; 8: 339ra71. PMC4991773 27194729 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies this as a retrospective, single-center study and reports associations between microbiota injury and GVHD severity. The copy also discusses GVHD-related mortality, but it does not establish the attributed links to relapse, infection, organ toxicity, or overall survival as distinct outcomes. (LLM, conf=0.84)
- Not checked yetcites [11] Hidaka D, Hayase E, Shiratori S, The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation. Clin Transplant 2018; 32(9): e13361. 30054935 source
- Supportedcites [12] Peled JU, Devlin SM, Staffas A, Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol 2017; 35: 1650– 9. 28296584 PMC5455763 source
The Discussion reports that this retrospective, single-center study found an association between intestinal bacterial abundance and decreased relapse risk after allo-HCT. The Introduction also identifies GVHD, bloodstream infections, organ toxicity, and overall survival as outcomes associated with intestinal bacterial composition; this paper's own contribution to the multi-cited sentence is the relapse association. (LLM, conf=0.92)
- Partly supportedcites [13] Ubeda C, Taur Y, Jenq RR, Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120: 4332– 41. 21099116 PMC2993598 sourceExperimental — accuracy not yet measured
The section on VRE intestinal colonization in humans reports that Enterococcus dominance preceded bloodstream infection in two allo-HSCT patients, supporting the infection portion of the citing sentence. Our copy does not link post-transplant microbiota features to relapse, GVHD, organ toxicity, or overall survival. Page numbers are not available in the indexed passages. (LLM, conf=0.86)
- Not checked yetcites [14] Haak BW, Littmann ER, Chaubard JL, Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 2018; 131: 2978– 86. 29674425 PMC6024637
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results of this international study extend previous observations that have been made in smaller, single-center cohorts.3,4,8,36”
§ Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation > DISCUSSION
What the sources say
- Supportedcites [3] Taur Y, Xavier JB, Lipuma L, Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905– 14. 22718773 PMC3657523 source
The Study Patients and Specimen Collection section identifies a cohort recruited at one center, Memorial Sloan-Kettering Cancer Center. The Development of Intestinal Domination section reports observations from 94 patients. This supports citing the paper as an example of an earlier, single-center cohort; the paper itself does not establish the international study’s size. (LLM, conf=0.90)
- Supportedcites [4] Golob JL, Pergam SA, Srinivasan S, Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin Infect Dis 2017; 65: 1984– 91. 29020185 PMC5850019 source
The Discussion identifies the cited paper as a single-center study and reports stool-microbiome findings associated with severe acute GVHD. The Results list 66 participants (Table 1). The 'international study' is the citing authors’ study, not a description attributed to this source. (LLM, conf=0.89)
- Supportedcites [8] Taur Y, Jenq RR, Perales MA, The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124: 1174– 82. 24939656 PMC4133489 source
The citation supports the sentence’s reference to an earlier, smaller single-center cohort, not its description of the citing authors’ international study. The Results describe 80 patients at MSKCC, and the Discussion reports the earlier observation that lower intestinal microbial diversity was associated with mortality after transplant. Page numbers were not available in our copy. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The central analysis of samples in this study was another important element because both wet-laboratory processing and computational pipelines are critical factors in the reproducibility and quality of microbiota data.45”
§ Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation > DISCUSSION
What the sources say
- Supportedcites [45] Sinha R, Abu-Ali G, Vogtmann E, Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium. Nat Biotechnol 2017; 35: 1077– 86. 28967885 PMC5839636 source
The part of the citing sentence offered to this source is the rationale — that wet-laboratory processing and computational pipelines are critical to microbiota data quality and reproducibility. Our copy states exactly this in the Discussion ('each microbiome protocol step, including sample handling environment, DNA extraction, and bioinformatic processing has the potential to introduce variation of comparable effect size to that of biological differences... almost any data generation or analysis protocol choice has the potential to yield divergent results'), framed around improving 'reproducibility and rigor of microbiome analyses', and in the Results ('standardization efforts themselves need to be scaled up'). The paper also operationalizes the centralization rationale, using centrally extracted DNA to separate extraction-driven variation (Results, 'Variation due to extraction protocol'; Online Methods, 'Central DNA extraction'). The 'central analysis in this study' clause is the citing authors' own design choice, not an assertion about MBQC, and the mild caveat that bioinformatics and sequencing effects were typically smaller than data-generation effects does not contradict the claim as hedged. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Preclinical models have shown that commensal bacteria influence the pathophysiology of GVHD.10,17–20”
§ Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation > Abstract > CONCLUSIONS
What the sources say
- Supportedcites [10] Shono Y, Docampo MD, Peled JU, Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 2016; 8: 339ra71. PMC4991773 27194729 source
The Introduction (p.1) states that 'commensal bacteria can be potent modulators of the severity of GVHD' and that GVHD is accompanied by bacterial shifts from Clostridiales to Lactobacillales/Enterobacteriales. Our copy's own mouse work supports the broad claim: the Discussion states that prior gut-decontamination work and metronidazole-ciprofloxacin data lend 'support to the hypothesis that intestinal bacteria contribute to GVHD pathophysiology,' and the paper demonstrates in mice that antibiotic-driven loss of Clostridiales with expansion of Akkermansia muciniphila exacerbated colonic GVHD (Abstract; RESULTS, 'Imipenem-cilastatin treatment of mice with GVHD resulted in an increase in the Akkermansia strain in the colon'; DISCUSSION). The citing sentence is a broad background statement exemplified by this preclinical source, so it is supported; the specific mechanistic attributions (e.g. Blautia loss, refs 11-13,15) belong to other works, but the general point holds. (LLM, conf=0.85)
- Not checked yetcites [17] van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401– 4. 4150164 source
- Supportedcites [18] Mathewson ND, Jenq R, Mathew AV, Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 2016; 17: 505– 13. 26998764 PMC4836986 source
The RESULTS section 'High butyrate producing microbiota mitigate GVHD' reports experimental (murine) allo-BMT work showing commensal bacteria alter GVHD: gavage of naive/BMT recipient mice with 17 rationally selected Clostridia strains shifted the indigenous microbiota, raised luminal and intestinal butyrate, and produced 'significantly decreased GVHD' and 'significantly increased survival', including at a second institution and after antibiotic depletion of obligate anaerobes (where non-recolonized mice 'died significantly faster (P<0.0001)'). The Abstract likewise states that 'alteration of the indigenous microbiota with 17 rationally selected strains of high butyrate producing Clostridia also decreased GVHD'. This matches the attributed paraphrase that preclinical/animal models show commensal bacteria influence GVHD pathophysiology. (LLM, conf=0.90)
- Supportedcites [19] Jenq RR, Ubeda C, Taur Y, Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209: 903– 11. 22547653 PMC3348096 source
Our copy directly supports the attributed point: the Figure 3 legend states 'Composition of intestinal flora can impact on severity of intestinal GVHD,' and the Results and Discussion report that ampicillin depletion of commensal flora before BMT worsened GVHD survival and intestinal pathology while reintroduction of the commensal L. johnsonii (of B6 flora origin) prevented that increased lethality and pathology. The concluding paragraph generalises this as 'The flora, in turn, can modulate severity of intestinal inflammation' after allogeneic BMT, and the Abstract frames the mouse work as readdressing the GVHD-microbiota relationship. These are preclinical (murine B10.BR→B6 and B6→BM12) models, matching 'preclinical models' in the citing sentence. (LLM, conf=0.90)
- Supportedcites [20] Stein-Thoeringer CK, Nichols KB, Lazrak A, Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 2019; 366: 1143– 9. 31780560 PMC7003985 source
Our copy of Stein-Thoeringer et al. (2019) directly demonstrates the attributed point in preclinical models: gnotobiotic C57BL/6 and conventionally housed BALB/c allo-HCT recipients colonized with the commensal E. faecalis OG1RF showed exacerbated GVHD, elevated serum IFNγ, and increased activated/proliferating and Th17 donor CD4+ T-cells (Abstract/Results, p. ~5-6, passages incl. Fig. 2D, S4B-D, S5A). The Discussion (p. ~11) states plainly that 'In gnotobiotic mouse models, enterococci exacerbate GVHD,' and the lactose-free-diet experiments (Fig. 4A-B) show that removing a dietary substrate for a commensal taxon reduced the Enterococcus bloom and mitigated GVHD. The same passage also credits the broader commensal-GVHD link (prior Blautia-abundance protection, ref. 12), so the general statement that commensal bacteria influence GVHD pathophysiology is squarely supported. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For example, domination of intestinal communities by a single bacterial taxon leads to an increased risk of bloodstream infection by a bacterium of that same taxon,3”
§ Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [3] Taur Y, Xavier JB, Lipuma L, Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905– 14. 22718773 PMC3657523 sourceExperimental — accuracy not yet measured
The Association of Intestinal Domination With Bacteremia section reports that enterococcal domination predicted a 9-fold higher risk of VRE bacteremia and proteobacterial domination a 5-fold higher risk of gram-negative bacteremia. This supports the same-taxon risk association, but the study concerns patients undergoing allogeneic stem cell transplantation and does not establish that domination causes infection generally. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
27 more claims
Create a free account to see all 51 claims and to verify the 9 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 9
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Associations between alpha diversity and cancer patient outcomes have been found in the setting of patients receiving hematopoietic cell transplant 29 or cervical cancer chemoradiation 30 but not in anti-PD-1 recipients with metastatic melanoma 16,18 ; thus, such associations may be treatment regimen specific.”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [29]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Research works printed but not linked: 1
- Legendre P, Legendre L. Numerical ecology. 3rd ed. Amsterdam: Elsevier, 2012.
Cited by
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“The effects of gut microbiota on primary lymphoid organs After allogeneic hematopoietic stem cell transplantation (HSCT), robust immune reconstitution governs both relapse and transplant-related patientmortality (56, 57).”
BackgroundInfluentialThe gut microbiota is associated with immune cell dynamics in humans
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., et al. (2020) · Nature · doi:10.1038/s41586-020-2971-8 · Cited by 601
Self-citationGut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 588
Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites
Guo, H., Chou, W.-C., Lai, Y., Liang, K., Tam, J. W., Brickey, W. J., Chen, L., Montgomery, N. D., Li, X., Bohannon, L. M., et al. (2020) · Science · doi:10.1126/science.aay9097 · Cited by 561
“DNA extraction, polymerase chain reaction amplification of genomic 16S ribosomal RNA V4 and V5 regions, and sequencing were performed as previously described (30).”
MethodSelf-citationSorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Self-citation
Metadata
- Authors
- Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber, D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., Maloy, M., Clurman, A. G., Stein-Thoeringer, C. K., Markey, K. A., Docampo, M. D., Burgos da Silva, M., Khan, N., Gessner, A., Messina, J. A., Romero, K., Lew, M. V., Bush, A., Bohannon, L., Brereton, D. G., Fontana, E., Amoretti, L. A., Wright, R. J., Armijo, G. K., Shono, Y., Sanchez-Escamilla, M., Castillo Flores, N., Alarcon Tomas, A., Lin, R. J., Yáñez San Segundo, L., Shah, G. L., Cho, C., Scordo, M., Politikos, I., Hayasaka, K., Hasegawa, Y., Gyurkocza, B., Ponce, D. M., Barker, J. N., Perales, M.-A., Giralt, S. A., Jenq, R. R., Teshima, T., Chao, N. J., Holler, E., Xavier, J. B., Pamer, E. G., & van den Brink, M. R. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Adult Bone Marrow Transplantation Service (J.U.P., M.M., A.G.C., K.A.M., N.K., D.G.B., M.S.-E., N.C.F., A.A.T., R.J.L., L.Y.S.S., G.L.S., C.C., M.S., I.P., B.G., D.M.P., J.N.B., M.-A.P., S.A.G., M.R.M.B.) and the Infectious Disease Service (Y.T., E.F., L.A.A., R.J.W., E.G.P.), Department of Medicine, the Department of Epidemiology and Biostatistics (S.M.D.), the Department of Immunology, Sloan Kettering Institute (A.L.C.G., E.R.L., A.E.S., J.B.S., C.K.S.-T., M.D.D., M.B.S., G.K.A., Y.S., M.R.M.B.), and the Program for Computational and Systems Biology (J.B.X.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Weill Cornell Medical College (J.U.P., Y.T., K.A.M., M.D.D., R.J.L., G.L.S., C.C., M.S., I.P., B.G., D.M.P., J.N.B., M.-A.P., S.A.G., M.R.M.B.) — both in New York; Duchossois Family Institute of the University of Chicago, Chicago (E.R.L., E.G.P.); the Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center (A.D.S...
- ORCID
- Peled, Jonathan U.
- Gomes, Antonio L.C.
- Devlin, Sean M.
- Littmann, Eric R.
- Taur, Ying
- Sung, Anthony D.
- Weber, Daniela
- Hashimoto, Daigo
- Slingerland, Ann E.
- Slingerland, John B.
- Maloy, Molly
- Clurman, Annelie G.
- Markey, Kate A.
- Docampo, Melissa D.
- Khan, Niloufer
- Gessner, André
- Messina, Julia A.
- Romero, Kristi
- Lew, Meagan V.
- Bush, Amy
- Bohannon, Lauren
- Brereton, Daniel G.
- Fontana, Emily
- Amoretti, Luigi A.
- Wright, Roberta J.
- Armijo, Gabriel K.
- Shono, Yusuke
- Lin, Richard J.
- Shah, Gunjan L.
- Cho, Christina
- Scordo, Michael
- Politikos, Ioannis
- Hasegawa, Yuta
- Gyurkocza, Boglarka
- Ponce, Doris M.
- Barker, Juliet N.
- Perales, Miguel-Angel
- Giralt, Sergio A.
- Jenq, Robert R.
- Teshima, Takanori
- Chao, Nelson J.
- Holler, Ernst
- Pamer, Eric G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 822-834
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7534690
- OpenAlex
- W3008229386
- Semantic Scholar
- d8e6f29c481e4df68b6dc627853bc56f8c01efd7
- Cited by
- 765
- References
- 46
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 92 · 2023: 134 · 2022: 127 · 2021: 104 · 2020: 77
- FWCI
- 35.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- Tri-Institutional Stem Cell Initiative (2016-013)
- Lymphoma Foundation
- The Susan and Peter Solomon Divisional Genomics Program
- The Parker Institute for Cancer Immunotherapy
- The Sawiris Foundation
- Society of Memorial Sloan Kettering Cancer Center
- Memorial Sloan Kettering Center for Cancer Systems Immunology
- New York State Department of Health
- Seres Therapeutics
- Japan Society for the Promotion of Science (17H04206, 17K09945)
- Center of Innovation Program
- Theodore and Laura Hromadka
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Conquer Cancer Foundation
- National Center for Advancing Translational Sciences (KL2 TR001115-03)
- National Institutes of Health (R01 AI032135)
- National Cancer Institute (1R01CA228308-01, 1R01CA228358-01, P01-CA023766 (Project 4), P30 CA008748, R01-HL125571, R01CA203950-01, U01 AI124275)
- National Heart, Lung, and Blood Institute (1R01HL124112-01A, K08HL143189-01A1, R01-HL123340, R01-HL125571)
- National Institute on Aging (2P30AG028716-11, P01-AG052359 (Project 2))
- National Institute of Allergy and Infectious Diseases (AI095706, R01 AI137269-01, U01 AI124275)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- gut microbiota, allogeneic hematopoietic stem cell transplantation, microbiome diversity, mortality, transplantation-related mortality, graft-versus-host disease, microbiome disruption, fecal microbiota, 16S rRNA gene sequencing, neutrophil engraftment, post-transplant survival
- MeSH terms
- Gastrointestinal Microbiome, Adult, Feces, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Transplantation, Homologous, Survival Analysis, Hematopoietic Stem Cell Transplantation, Biodiversity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. https://app.cochat.ai/papers/10.1056/nejmoa1900623
- The paper
- Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., Weber, D., Hashimoto, D., Slingerland, A. E., Slingerland, J. B., Maloy, M., Clurman, A. G., Stein-Thoeringer, C. K., Markey, K. A., Docampo, M. D., Burgos da Silva, M., Khan, N., Gessner, A., Messina, J. A., . . . van den Brink, M. R. M. (2020). Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1900623
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.